STOCK TITAN

Relay Therapeutics (RLAY): Perceptive Advisors discloses 6.4% ownership stake

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of Common Stock of Relay Therapeutics, Inc. The Master Fund directly holds 14,106,187 shares of Common Stock. Based on 219,141,631 shares outstanding as of July 31, 2026, this represents 6.4% of the class for each Reporting Person. All 14,106,187 shares are reported with shared power to vote and shared power to dispose, and 0 shares are reported with sole voting or dispositive power. Perceptive Advisors acts as investment manager to the Master Fund, and Joseph Edelman, as managing member of Perceptive Advisors, may be deemed to beneficially own the shares held by the Master Fund.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 14,106,187 shares Common Stock of Relay Therapeutics held by Perceptive Life Sciences Master Fund, Ltd.
Percent of class owned 6.4% Beneficial ownership percentage for each Reporting Person
Shares outstanding 219,141,631 shares Common Stock outstanding as of July 31, 2026
Shared voting power 14,106,187 shares Shares over which each Reporting Person has shared power to vote
Sole voting power 0 shares Shares over which each Reporting Person has sole power to vote
beneficially own financial
"may be deemed to beneficially own the shares held by the Master Fund"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared voting power financial
"Shared Voting Power 14,106,187.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 14,106,187.00"
investment manager financial
"Perceptive Advisors serves as the investment manager to the Master Fund"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How much of Relay Therapeutics (RLAY) stock is owned by Perceptive entities?

Perceptive Life Sciences Master Fund directly holds 14,106,187 shares of Relay Therapeutics Common Stock, representing 6.4% of the outstanding shares based on 219,141,631 shares outstanding as of July 31, 2026.

Who are the reporting persons in this Schedule 13G/A for Relay Therapeutics (RLAY)?

The reporting persons are Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd.. Perceptive Advisors is investment manager to the Master Fund, and Edelman is Perceptive Advisors’ managing member.

What percentage of Relay Therapeutics (RLAY) does Perceptive Advisors report owning?

Perceptive Advisors reports beneficial ownership of 6.4% of Relay Therapeutics’ Common Stock, corresponding to 14,106,187 shares, calculated using 219,141,631 shares outstanding as of July 31, 2026.

What voting and dispositive powers are reported over Relay Therapeutics (RLAY) shares?

Each reporting person reports 0 shares with sole voting or dispositive power and 14,106,187 shares with shared voting and shared dispositive power over Relay Therapeutics Common Stock.





75943R102

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:08/10/2026
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:08/10/2026
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:08/10/2026